Evaluation of Seropositivity Following BNT162b2 Messenger RNA Vaccination for SARS-CoV-2 in Patients Undergoing Treatment for Cancer

Cohort study in 102 patients and 78 healthy controls suggest patients with cancer who are receiving active treatment and are at higher risk for severe COVID-19 disease respond well to messenger RNA SARS-CoV-2 vaccines (90% seropositive after 2nd dose vs. 100% controls)

JAMA Oncology